Results 121 to 130 of about 50,573 (248)

Postoperative Care and Management in Pediatric Hematology‐Oncology Patients

open access: yesEuropean Journal of Haematology, Volume 117, Issue 3, Page 673-681, September 2026.
ABSTRACT Pediatric patients with hematologic and oncologic diseases often undergo surgical procedures as part of diagnosis and therapy. These include central venous catheter placements, tumor resections, lymph node and bone marrow biopsies, among others.
Shachi Srivatsa, Sara A. Mansfield
wiley   +1 more source

Localised malignant mesothelioma presenting as an esophageal mass: An unusual manifestation. [PDF]

open access: yesRadiol Case Rep
Yaxley KL   +4 more
europepmc   +1 more source

Consistency of c‐Met protein overexpression over time in patients with non‐squamous non‐small cell lung cancer

open access: yesHistopathology, Volume 89, Issue 3, Page 456-466, September 2026.
c‐Met protein overexpression can be assessed before or after treatment in patients with non‐squamous NSCLC since most patients maintain a consistent c‐Met status. However, as targeted therapies may elevate c‐Met overexpression, retesting may be necessary for subsets of patients.
Alexis B Cortot   +14 more
wiley   +1 more source

Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non‐Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study

open access: yesInternational Journal of Cancer, Volume 159, Issue 4, Page 985-996, 15 August 2026.
The optimal timing of surgery after neoadjuvant immunochemotherapy (NICT) for locally advanced non‐small cell lung cancer (NSCLC) remains unclear. In this retrospective investigation, the impact of time interval on outcome was assessed among NSCLC patients who completed NICT before undergoing radical resection.
Jiayi Wang   +12 more
wiley   +1 more source

Idiopathic Orbital Inflammation Masquerading as Relapse of Seronegative Juvenile Myasthenia Gravis: A Case Report

open access: yes
Journal of Paediatrics and Child Health, EarlyView.
Wenhao Duan   +4 more
wiley   +1 more source

Long‐term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study

open access: yesAlzheimer's &Dementia, Volume 22, Issue 8, August 2026.
Abstract INTRODUCTION ABvac40 is an active immunotherapy targeting Aβ40, the main component of cerebrovascular deposition in Alzheimer's disease (AD). A 24‐month randomized, placebo‐controlled phase 2 study (Part A) showed favorable safety and robust immunogenicity, with exploratory signals of clinical efficacy.
María Pascual‐Lucas   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy